ClinicalTrials.gg
CompletedNCT03770403ADAPT+Updated Jul 14, 2023Results posted

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

A Phase 3 interventional study of ARGX-113 in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 52 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-14.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Enrollment
3rd of 20
151 · median 55
Started
2019
the only one that year
Phase 3
10 of 20
3 open now
Registered
3rd of 20
by date
Lead sponsor
12 of 20
argenx

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 3rd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with the ability to understand the requirements of the trial, provide written , and comply with the trial protocol procedures.
  2. Patients who participated in trial ARGX-113-1704 and are eligible for roll over, as specified in the protocol.

Other more specific inclusion criteria are further defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients who discontinued early from trial ARGX-113-1704 or patients who discontinued early from randomized treatment for pregnancy or rescue reasons or an (S)AE that might jeopardize the safety of the patient in that trial.
  2. Pregnant and lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing. Women or should have a negative urine pregnancy test at SEB.
  3. Male patients who are sexually active and do not intend to use effective methods of during the trial or within 90 days after the last dosing or male patients who plan to donate sperm during the trial or within 90 days after the last dosing.
  4. Patients with known Virus (HBV), Virus (HCV) or (HIV) seropositivity.

Other, more specific exclusion criteria are further defined in the protocol.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    ARGX-113

    Biological: ARGX-113

Interventions

  • BiologicalARGX-113

    Intravenous administration of ARGX-113

    Also known as: efgartigimod

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in AChR-Positive Participants

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (electrocardiogram \[ECG\], radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. A serious AE (SAE) was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.

    Time frame: TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years

Secondary outcomes

  1. Number of Participants With TEAEs, Treatment-Emergent SAEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in the Overall Population

    Overall population included both AChR-Ab seropositive and AChR-Ab seronegative participants. An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (ECG, radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.

    Time frame: TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years

07

Results

Posted Jul 14, 2023

Participant flow

This Phase III, open-label study was a follow-on study of ARGX-113-1704 (NCT03669588) and was conducted in participants with myasthenia gravis having generalized muscle weakness at 51 investigational sites in 14 countries between 01 Mar 2019 and 30 Jun 2022. This study was conducted in 2 sequential parts: Part A (1 year) and Part B (\<=2 years).

Participant flow — Overall Study
MilestoneEfgartigimod
Started145
Completed28
Not completed117
Withdrew: Adverse event8
Withdrew: Death5
Withdrew: Physician decision1
Withdrew: Sponsor decision1
Withdrew: Study terminated by sponsor1
Withdrew: Withdrawal by subject13
Withdrew: Other88

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in AChR-Positive Participants

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (electrocardiogram \[ECG\], radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. A serious AE (SAE) was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.

Time frame:
TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in AChR-Positive Participants
ParticipantsEfgartigimod
TEAE92
Treatment-emergent SAE28
TEAEs leading to study drug discontinuation10
Fatal TEAE4
SecondaryNumber of Participants With TEAEs, Treatment-Emergent SAEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in the Overall Population

Overall population included both AChR-Ab seropositive and AChR-Ab seronegative participants. An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (ECG, radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.

Time frame:
TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years
Reported as:
Count of participants · Participants
Number of Participants With TEAEs, Treatment-Emergent SAEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in the Overall Population
ParticipantsEfgartigimod
TEAE124
Treatment-emergent SAE36
TEAEs leading to study drug discontinuation12
Fatal TEAE5

Adverse events

Collected over TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod5/145 (3.4%)36/145 (24.8%)83/145 (57.2%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventEfgartigimod
Myasthenia gravisNervous system disorders7/145
Cardiac failure congestiveCardiac disorders2/145
COVID-19Infections and infestations2/145
COVID-19 pneumoniaInfections and infestations2/145
PneumoniaInfections and infestations2/145
Myasthenia gravis crisisNervous system disorders2/145
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/145
AnaemiaBlood and lymphatic system disorders1/145
Acute myocardial infarctionCardiac disorders1/145
ArrhythmiaCardiac disorders1/145
Most frequent other events
Most frequent other events
EventEfgartigimod
HeadacheNervous system disorders36/145
NasopharyngitisInfections and infestations20/145
COVID-19Infections and infestations16/145
DiarrhoeaGastrointestinal disorders13/145
Urinary tract infectionInfections and infestations12/145
ArthralgiaMusculoskeletal and connective tissue disorders12/145
PyrexiaGeneral disorders11/145
NauseaGastrointestinal disorders9/145
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/145
HypertensionVascular disorders8/145

Baseline characteristics

The Safety Analysis set consisted of all participants who rolled over from ARGX-113-1704 and received \>=1 dose or part of a dose of efgartigimod in this study.

Age, Continuous
Age, Continuous(years)Efgartigimod
Mean47.0 ± 14.76
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod
Female103
Male42
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod
American Indian or Alaska Native2
Asian11
Black or African American5
White126
Multiple1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod
Japanese10
Hispanic or Latino9
Not Hispanic or Latino126
Anti-acetylcholine receptor antibodies (AChR-Ab) status
Anti-acetylcholine receptor antibodies (AChR-Ab) status(Participants)Efgartigimod
AChR-Ab seropositive111
AChR-Ab seronegative34
08

Study locations

52 sites
  • Investigator Site 42
    Carlsbad, California 92011, United States
  • Investigator Site 8
    Los Angeles, California 90033, United States
  • Investigator Site 33
    Orange, California 92868, United States
  • Investigator Site 21
    Palo Alto, California 94304, United States
  • Investigator Site 41
    Jacksonville, Florida 32209, United States
  • Investigator Site 4
    Tampa, Florida 33612, United States
  • Investigator Site 14
    Kansas City, Kansas 66160, United States
  • Investigator Site 32
    Detroit, Michigan 48201, United States
  • Investigator Site 2
    Chapel Hill, North Carolina 27599, United States
  • Investigator Site 18
    Cleveland, Ohio 44195, United States
  • Investigator Site 12
    Portland, Oregon 97239, United States
  • Investigator Site 1
    Cordova, Tennessee 38018, United States
  • Investigator Site 3
    San Antonio, Texas 78229, United States
  • Investigator Site 37
    Charlottesville, Virginia 22908, United States
  • Investigator Site 11
    Edegem, 2650, Belgium
  • Investigator Site 7
    Ghent, 9000, Belgium
  • Investigator Site 20
    Toronto, Ontario M5G 2C4, Canada
  • Investigator Site 25
    Montréal, Quebec H3A 2B4, Canada
  • Investigator Site 16
    Brno, 625 00, Czechia
  • Investigator Site 19
    Ostrava-Poruba, 70852, Czechia
  • Investigator Site 30
    Praha, 12800, Czechia
  • Investigator Site 49
    Aarhus, Denmark
  • Investigator Site 17
    Copenhagen, DK-2100, Denmark
  • Investigator Site 50
    Bordeaux, France
  • Investigator Site 51
    Marseille, France
  • Investigator Site 45
    Tbilisi, 0112, Georgia
  • Investigator Site 31
    Tbilisi, 0114, Georgia
  • Investigator Site 46
    Tbilisi, 0114, Georgia
  • Investigator Site 28
    Berlin, 10117, Germany
  • Investigator Site 35
    Budapest, 1204, Hungary
  • Investigator Site 52
    Szeged, Hungary
  • Investigator Site 10
    Milano, MI 20133, Italy
  • Investigator Site 5
    Napoli, 80131, Italy
  • Investigator Site 38
    Roma, 00189, Italy
  • Investigator Site 24
    Sapporo, Hokkaido 060-8543, Japan
  • Investigator Site 13
    Hanamaki-shi, Iwate 025-0075, Japan
  • Investigator Site 27
    Sendai, Miyagi 983-8520, Japan
  • Investigator Site 22
    Suita, Osaka 565-0871, Japan
  • Investigator Site 23
    Ōsaka-sayama, Osaka 589-8511, Japan
  • Investigator Site 40
    Meguro, Tokyo 153-8515, Japan
  • Investigator Site 43
    Shinjuku-Ku, Tokyo 160-0023, Japan
  • Investigator Site 47
    Chiba, Japan
  • Investigator Site 44
    Hiroshima, 730-8518, Japan
  • Investigator Site 48
    Minato, Japan
  • Investigator Site 36
    Leiden, 2333 ZA, Netherlands
  • Investigator Site 9
    Gdańsk, 80-952, Poland
  • Investigator Site 29
    Katowice, 40-123, Poland
  • Investigator Site 6
    Kraków, 31-505, Poland
  • Investigator Site 15
    Warszawa, 02-097, Poland
  • Investigator Site 34
    Novosibirsk, 630087, Russian Federation
  • Investigator Site 39
    Samara, 443095, Russian Federation
  • Investigator Site 26
    Belgrade, 11000, Serbia
09

References and documents

Publications

  • Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Erratum In: Lancet Neurol. 2021 Aug;20(8):e5. doi: 10.1016/S1474-4422(21)00216-7. PubMed 34146511 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jun 2022, 39 months.

Results were first posted in Jul 2023, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 39 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2018
First posted
Dec 10, 2018
StartActual
Mar 1, 2019
Primary completionActual
Jun 23, 2022
CompletionActual
Jun 30, 2022
Results first posted
Jul 14, 2023
Last update
Jul 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03770403
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Dec 10, 2018
Start date
Mar 1, 2019
Primary completion
Jun 23, 2022
Completion
Jun 30, 2022
Results posted
Jul 14, 2023
Last update
Jul 14, 2023

Study contacts

Sabine Coppieters, MD
study director · argenx

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion